
JuliÃ;n CarriÃ³n-Penagos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5159071/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet, The, 2019, 393, 1021-1032.	13.7	534
2	Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure. Neurosurgery, 2019, 84, 1157-1168.	1.1	93
3	Comprehensive transcriptome analysis of cerebral cavernous malformation across multiple species and genotypes. JCI Insight, 2019, 4, .	5.0	40
4	Transcriptome clarifies mechanisms of lesion genesis versus progression in models of Ccm3 cerebral cavernous malformations. Acta Neuropathologica Communications, 2019, 7, 132.	5.2	27
5	Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma. Nature Communications, 2020, 11, 2659.	12.8	27
6	Biomarkers of cavernous angioma with symptomatic hemorrhage. JCl Insight, 2019, 4, .	5.0	25
7	Intracerebral Hemorrhage Volume Reduction and Timing of Intervention Versus Functional Benefit and Survival in the MISTIE III and STICH Trials. Neurosurgery, 2021, 88, 961-970.	1.1	24
8	Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation. GeroScience, 2020, 42, 1351-1363.	4.6	11
9	Phantom validation of quantitative susceptibility and dynamic contrastâ€enhanced permeability MR sequences across instruments and sites. Journal of Magnetic Resonance Imaging, 2020, 51, 1192-1199.	3.4	10
10	Perfusion and Permeability <scp>MRI</scp> Predicts Future Cavernous Angioma Hemorrhage and Growth. Journal of Magnetic Resonance Imaging, 2022, 55, 1440-1449.	3.4	9
11	Thrombolysis for Evacuation of Intracerebral and Intraventricular Hemorrhage: A Guide to Surgical Protocols With Practical Lessons Learned From the MISTIE and CLEAR Trials. Operative Neurosurgery, 2020, 20, 98-108.	0.8	8
12	Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance. Journal of Neurosurgery, 2020, 134, 1-8.	1.6	8
13	Clinical and electrophysiological characteristics of Guillainâ€Barré syndrome in Colombia. Journal of the Peripheral Nervous System, 2019, 24, 268-271.	3.1	7
14	Symptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the Literature. World Neurosurgery, 2020, 136, 7-11.	1.3	7
15	Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2944-2956.	4.3	6
16	Baseline Characteristics of Patients With Cavernous Angiomas With Symptomatic Hemorrhage in Multisite Trial Readiness Project. Stroke, 2021, 52, 3829-3838.	2.0	6
17	Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu. Journal of Autoimmunity, 2020, 113, 102469.	6.5	4

18 Management of Intraventricular Hemorrhage. , 2022, , 1055-1065.e3.

0

#	Article	IF	CITATIONS
19	Abstract TMP107: Microbiome Signature of Cerebral Cavernous Malformation Patients. Stroke, 2019, 50, .	2.0	0
20	Abstract 64: Novel and Known Genes Elucidated in Cerebral Cavernous Malformation Through Comparative Transcriptomic Analysis of Multiple Model Species and Human Microdissected Lesional Endothelial Cells. Stroke, 2019, 50, .	2.0	0
21	Abstract WMP103: Comparative Impact of Extent of Lobar Intracerebral Hemorrhage Removal on Outcome in the MISTIE III and STICH II Trials. Stroke, 2020, 51, .	2.0	0
22	Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease. Translational Stroke Research, 0, , .	4.2	0